scholarly journals MRI measures of hypothalamic injury are associated with GLP ‐1 receptor agonist treatment response in people with hypothalamic obesity

2021 ◽  
Author(s):  
Francisco A. Perez ◽  
Clinton Elfers ◽  
Jack A. Yanovski ◽  
Ashley H. Shoemaker ◽  
M. Jennifer Abuzzahab ◽  
...  
Keyword(s):  
Treatment Response ◽  
Receptor Agonist ◽  
Hypothalamic Obesity ◽  
Hypothalamic Injury

Cholecystokinin and satiety: effect of hypothalamic obesity and gastric bubble insertion

1992 ◽  
Vol 262 (2) ◽  
pp. R241-R244
Author(s):  
M. G. Boosalis ◽  
N. Gemayel ◽  
A. Lee ◽  
G. A. Bray ◽  
L. Laine ◽  
...  
Keyword(s):  
Gastric Volume ◽  
Time Dependent ◽  
Dependent Manner ◽  
Hypothalamic Obesity ◽  
Double Blind ◽  
Afferent Fibers ◽  
Hypothalamic Injury ◽  
Obese Subjects ◽  
Vagal Afferent ◽  
Gastric Bubble

Cholecystokinin (CCK) is a gut peptide whose proposed effect on satiety is thought to be related to gastric volume and to be signaled through vagal afferent fibers to the medial hypothalamus. To test these hypotheses we infused CCK C-terminal octapeptide (CCK-8) or saline in a random double-blind fashion in three groups of subjects: 17 obese subjects, 6 of whom subsequently received a gastric bubble, and 5 obese subjects whose obesity was due to hypothalamic injury. The number of sandwich canapes eaten after saline or CCK-8 infusion was recorded during three consecutive 10-min eating periods. Each subject served as his/her own control. The prior infusion of CCK-8 significantly decreased the consumption of sandwich canapes in the first eating period in both the control obese subjects and the subjects with obesity due to hypothalamic injury. Insertion of a gastric bubble did not enhance the satiety effect of CCK-8. These studies support the hypothesis that CCK produces satiety in a time-dependent manner that is not enhanced after the insertion of a gastric bubble but is operative in obese subjects with hypothalamic injury.

scholarly journals Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag

2011 ◽  
Vol 1 (1) ◽  
pp. 5 ◽  
Author(s):  
Rajakrishnan Vijayakrishnan ◽  
Sourbha Dani ◽  
Aparna Ramasubramanian ◽  
Rekha Nair ◽  
Tony M. Samaha
Keyword(s):  
Hepatitis C ◽  
Antiretroviral Therapy ◽  
Treatment Response ◽  
Highly Active Antiretroviral Therapy ◽  
Standard Therapy ◽  
Receptor Agonist ◽  
Patient Treatment ◽  
Highly Active ◽  
Novel Agent ◽  
Haart Therapy

HIV-associated thrombocytopenia is a dis- ease which can be recurrent to standard therapy which includes highly active antiretroviral therapy (HAART) therapy, steroids and immunoglobulin. We report a patient with HIV and hepatitis C who presented with resistant thrombocytopenia. Treatment with Eltrombopag – a thrombopoeitin receptor agonist showed initial good response with recurrence of thrombocytopenia. This novel agent could be considered as a treatment option prior to splenectomy and may be useful as a tempo- rizing measure.

Author response for "A Phase 3 Randomized Clinical Trial using Once‐Weekly GLP ‐1 Receptor Agonist in Adolescents and Young Adults with Hypothalamic Obesity"

2020 ◽  
Author(s):  
Christian L. Roth ◽  
Francisco A. Perez ◽  
Kathryn B. Whitlock ◽  
Clinton Elfers ◽  
Jack A. Yanovski ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Young Adults ◽  
Randomized Clinical Trial ◽  
Receptor Agonist ◽  
Adolescents And Young Adults ◽  
Author Response ◽  
Hypothalamic Obesity ◽  
Phase 3

Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist

2022 ◽  
Author(s):  
Ashley H. Shoemaker ◽  
Heidi J. Silver ◽  
Maciej Buchowski ◽  
James C. Slaughter ◽  
Jack A. Yanovski ◽  
...  
Keyword(s):  
Energy Balance ◽  
Receptor Agonist ◽  
Response To Treatment ◽  
Hypothalamic Obesity
Sign in / Sign up

Export Citation Format

Share Document